CN115515484A - 使用磁共振波谱校准和选择鼻内施用n-乙酰半胱氨酸的剂量、制剂和装置 - Google Patents

使用磁共振波谱校准和选择鼻内施用n-乙酰半胱氨酸的剂量、制剂和装置 Download PDF

Info

Publication number
CN115515484A
CN115515484A CN202080091814.4A CN202080091814A CN115515484A CN 115515484 A CN115515484 A CN 115515484A CN 202080091814 A CN202080091814 A CN 202080091814A CN 115515484 A CN115515484 A CN 115515484A
Authority
CN
China
Prior art keywords
nac
administration
brain
gsh
pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080091814.4A
Other languages
English (en)
Chinese (zh)
Inventor
道格拉斯·A·格林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuronezel
Original Assignee
Nuronezel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuronezel filed Critical Nuronezel
Publication of CN115515484A publication Critical patent/CN115515484A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/483—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
CN202080091814.4A 2019-11-04 2020-11-04 使用磁共振波谱校准和选择鼻内施用n-乙酰半胱氨酸的剂量、制剂和装置 Pending CN115515484A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930473P 2019-11-04 2019-11-04
US62/930,473 2019-11-04
PCT/US2020/058905 WO2021092026A1 (en) 2019-11-04 2020-11-04 Use of magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of n-acetylcysteine

Publications (1)

Publication Number Publication Date
CN115515484A true CN115515484A (zh) 2022-12-23

Family

ID=75688247

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080091814.4A Pending CN115515484A (zh) 2019-11-04 2020-11-04 使用磁共振波谱校准和选择鼻内施用n-乙酰半胱氨酸的剂量、制剂和装置

Country Status (7)

Country Link
US (2) US20210128509A1 (https=)
EP (1) EP4054410A4 (https=)
JP (2) JP2023500360A (https=)
CN (1) CN115515484A (https=)
AU (1) AU2020380291A1 (https=)
CA (1) CA3160283A1 (https=)
WO (1) WO2021092026A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3618824A4 (en) * 2017-05-02 2021-06-23 Neuronasal, LLC USE OF N-ACETYLCYSTONE FOR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
US12594254B2 (en) * 2022-02-07 2026-04-07 Neuronasal, Inc. Intranasal administration of n-acetylcysteine and uses thereof
WO2023192691A2 (en) * 2022-04-01 2023-10-05 Wake Forest University Health Sciences Methods and formulations for intranasal delivery of insulin in the treatment of diabetic eye disease
US20250371713A1 (en) * 2024-05-28 2025-12-04 Debra Strick Rivera Mapping glutathione deficiency and/or dysfunction of mitochondria

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100099762A1 (en) * 2006-10-23 2010-04-22 The Mental Health Research Institute Of Victoria Combination therapy
US20150148423A1 (en) * 2012-04-26 2015-05-28 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
WO2018204393A1 (en) * 2017-05-02 2018-11-08 Neuronasal, Llc Use of n-acetylcysteine to treat central nervous system disorders
WO2019084543A1 (en) * 2017-10-27 2019-05-02 Beyond Barriers Therapeutics, Inc. ENHANCED ANTIOXIDANT ADMINISTRATION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INVOLVING OXIDATIVE STRESS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2844199T3 (es) * 2013-04-16 2021-07-21 Childrens Hospital Philadelphia Composiciones y métodos para el tratamiento de lesiones cerebrales
CA3165422A1 (en) * 2019-12-18 2021-06-24 Neuronasal, Inc. Methods of treating brain disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100099762A1 (en) * 2006-10-23 2010-04-22 The Mental Health Research Institute Of Victoria Combination therapy
US20150148423A1 (en) * 2012-04-26 2015-05-28 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
WO2018204393A1 (en) * 2017-05-02 2018-11-08 Neuronasal, Llc Use of n-acetylcysteine to treat central nervous system disorders
WO2019084543A1 (en) * 2017-10-27 2019-05-02 Beyond Barriers Therapeutics, Inc. ENHANCED ANTIOXIDANT ADMINISTRATION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INVOLVING OXIDATIVE STRESS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LK MISCHLEY ET AL.: "Central nervous system uptake of intranasal glutathione in Parkinson’s disease", NATURE PARTNER JOURNALS, 25 February 2016 (2016-02-25), pages 1 - 6 *

Also Published As

Publication number Publication date
JP2023500360A (ja) 2023-01-05
EP4054410A4 (en) 2024-07-17
US20210128509A1 (en) 2021-05-06
WO2021092026A1 (en) 2021-05-14
CA3160283A1 (en) 2021-05-14
AU2020380291A1 (en) 2022-05-26
EP4054410A1 (en) 2022-09-14
JP2025107344A (ja) 2025-07-17
US20230321020A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
US20230321020A1 (en) Magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of n-acetylcysteine
US12414929B2 (en) Methods of treating brain disorders
US7855176B1 (en) Reduced volume formulation of glatiramer acetate and methods of administration
US12440457B2 (en) Methods of treating suicidality
US20120232017A1 (en) Reduced volume formulation of glatiramer acetate and methods of administration
US20220249605A1 (en) Treatment of Mood and Anxiety Disorders
US20240024267A1 (en) Methods of administering glutathione precursors
WO2016057533A1 (en) Primary and secondary prevention of dementias and suicide with trace dose lithium
Akgun et al. Central nervous system stimulants and drugs that suppress appetite
RU2655763C2 (ru) Фармацевтическая композиция и способ лечения женских сексуальных дисфункций
HK40117702A (en) Liquid botulinum toxin composition for treating moderate to very severe glabellar lines and lateral canthal lines
WO2023099013A1 (en) Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury
HK1152249B (en) Reduced volume formulation of glatiramer acetate and methods of administration

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination